Corseaux Delphine, Ollivier Véronique, Fontaine Vincent, Huisse Marie-Geneviève, Philippe Monique, Louedec Liliane, Vranckx Roger, Ravanat Catherine, Lanza François, Angles-Cano Edouardo, Guillin Marie-Claude, Michel Jean-Baptiste
INSERM U479, Faculté Xavier Bichat, Paris, France.
Mol Med. 2002 Apr;8(4):169-78.
The rat model of chronic intoxication by N(G) -nitro-L-arginine methyl ester (L-NAME) induces severe systemic arterial hypertension and progressive ischemic lesions in the central nervous system and kidneys. We investigated the possible molecular basis of these thrombotic events.
Administration of L-NAME increased plasma markers of thrombin generation, thrombin-antithrombin complexes, and soluble glycoprotein V, measured by specific ELISA. Thrombin generation in vivo was associated with ex vivo platelet desensitization to adenosine 5'-diphosphate and collagen-induced aggregation. In the aortic layers and renal arterioles, tissue factor mRNA (semi-quantitative RT-PCR) and activity (coagulation assay) were increased. In contrast, tissue factor activity was not modified in glomeruli. In parallel, an impairment of the fibrinolytic system was demonstrated by an increase in plasma levels and arterial secretion of plasminogen activator inhibitor-1. In the arterial wall, plasminogen activator inhibtor-1 mRNA was significantly increased. Moreover, antifibrinolytic activity, studied by fibrin reverse zymography, was increased whereas all tissue-plasminogen activator activity secreted by the hypertensive arterial wall was detected as complexes with its specific inhibitor. In animals treated with the angiotensin-converting enzyme (ACE) inhibitor Zofenil, all of these parameters remained at control levels.
These results indicate that chronic blockade of nitric oxide production in rats results in enhancement of blood markers of thrombin generation associated with tissue factor induction and impairment of fibrinolysis in the vascular wall, which may contribute to the thrombotic complications associated with hypertension.
N(G)-硝基-L-精氨酸甲酯(L-NAME)慢性中毒大鼠模型可诱发严重的全身性动脉高血压以及中枢神经系统和肾脏的进行性缺血性病变。我们研究了这些血栓形成事件可能的分子基础。
通过特异性酶联免疫吸附测定法(ELISA)测量发现,给予L-NAME会增加凝血酶生成的血浆标志物、凝血酶-抗凝血酶复合物以及可溶性糖蛋白V。体内凝血酶生成与体外血小板对腺苷5'-二磷酸和胶原诱导聚集的脱敏有关。在主动脉层和肾小动脉中,组织因子mRNA(半定量逆转录聚合酶链反应)和活性(凝血测定)增加。相比之下,肾小球中的组织因子活性未改变。同时,血浆纤溶酶原激活物抑制剂-1水平升高以及动脉分泌增加表明纤溶系统受损。在动脉壁中,纤溶酶原激活物抑制剂-1 mRNA显著增加。此外,通过纤维蛋白反向酶谱法研究发现抗纤溶活性增加,而高血压动脉壁分泌的所有组织型纤溶酶原激活物活性均被检测为与其特异性抑制剂形成的复合物。在用血管紧张素转换酶(ACE)抑制剂佐芬尼尔治疗的动物中,所有这些参数均保持在对照水平。
这些结果表明,大鼠体内一氧化氮生成的慢性阻断会导致凝血酶生成的血液标志物增加,这与组织因子诱导以及血管壁纤溶功能受损有关,这可能导致与高血压相关的血栓形成并发症。